Ashish Life Science Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Ashish Life Science Private Limited Pharmaceutical Export Portfolio Dataset — 5 Products, $482.8K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ashish Life Science Private Limited — Pharmaceutical Exporter Profile (2026) | 5 Products, $482.8K Trade | TransData Nexus

Ashish Life Science Private Limited

Indian Pharmaceutical Exporter · Antimalarial & Antiparasitic Specialist · $482.8K Total Trade · DGFT Verified

Ashish Life Science Private Limited is an Indian pharmaceutical exporter with a total trade value of $482.8K across 5 products in 2 therapeutic categories. Based on 94 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ivermectin ($138.4K), Praziquantel ($101.9K), Levamisole ($93.6K).

Ashish Life Science Private Limited — Export Portfolio & Destination Treemap

Ashish Life Science Private Limited pharmaceutical export portfolio — 5 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Ashish Life Science Private Limited? — Company Overview & Market Position

Ashish Life Science Private Limited, established in 1992, is a prominent Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company is headquartered in Mumbai, Maharashtra, India, with its registered office located at 213, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai - 400053. As a private, non-government company, it is classified under the Corporate Identification Number (CIN) U24100MH1992PTC064810. The authorized capital stands at ₹53.55 million, with a paid-up capital of ₹47.95 million. Ashish Life Science is part of the Ashish Group of Industries, which has been operational since 1975. The company employs between 200 to 500 professionals, reflecting its substantial presence in the pharmaceutical manufacturing sector.

What Does Ashish Life Science Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ivermectin$138.4K 2Praziquantel

Product Portfolio — Top 5 by Export Value

Ashish Life Science Private Limited exports 5 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ivermectin	Antimalarial & Antiparasitic	$138.4K	43	1.6%	12
2	Praziquantel	Antimalarial & Antiparasitic	$101.9K	19	3.5%	5
3	Levamisole	Antimalarial & Antiparasitic	$93.6K	9	3.5%	7
4	Streptomycin	Antibiotics	$92.5K	3	16.1%	2
5	Pyrantel	Antimalarial & Antiparasitic	$56.4K	20	1.7%	8

Ashish Life Science Private Limited exports 5 pharmaceutical products across 2 therapeutic categories with a total export value of $482.8K. The top category is Antimalarial & Antiparasitic (80.8% of portfolio), followed by Antibiotics (19.2%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Ashish Life Science Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Ashish Life Science operates a state-of-the-art manufacturing facility located in Tarapur, Maharashtra, India. This plant has received approvals from the World Health Organization Good Manufacturing Practice (WHO GMP), European Union Good Manufacturing Practice (EU GMP), and the Australian Pesticides and Veterinary Medicines Authority (APVMA), underscoring its adherence to international quality standards. The facility is equipped with advanced technology and ergonomic infrastructure, enabling the production of a diverse range of veterinary dosage forms. These include water-soluble powders and granules in sachets and drums ranging from 5g to 25 kg, catering to both small and large-scale farmers, as well as extensive poultry and dairy operations. Additionally, the plant manufactures bolus and tablet formulations for large and small animals, demonstrating excellent bioequivalence properties in ruminants and non-ruminants. Oral liquid and paste formulations are produced in a dedicated unit with a daily capacity of 3,000 liters, offering customization in taste, color, and flavor to meet client specifications. The liquid injectable plant, covering 761 square meters, is equipped with ultra-modern machinery, including a fully automated tunnel with a PLC system, and has a filling capacity of 2,000 liters per day.

3Key Leadership

The leadership team at Ashish Life Science Private Limited is spearheaded by Managing Director Raujesh Agarrwal, who has been instrumental in steering the company's strategic direction and growth. (craft.co) The company's board of directors includes Rajkumar Harnathrai Agarwal, Prem Venkatachalam Pavoor, Parimal Merchant, Swati Raunak Phadnis, and Bhavik Bhupendra Parekh, each contributing their expertise to the company's operations and strategic initiatives. This diverse leadership team underscores the company's commitment to innovation, quality, and customer satisfaction in the pharmaceutical manufacturing sector.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Ashish Life Science Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Ashish Life Science Private Limited has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in Tarapur, Maharashtra, has been approved by the European Union Good Manufacturing Practice (EU GMP) and the Australian Pesticides and Veterinary Medicines Authority (APVMA), highlighting its compliance with stringent international standards. These approvals facilitate the company's market access in these regions, enabling it to export a range of veterinary pharmaceutical products. The company's adherence to international quality standards and regulatory requirements positions it favorably in these markets, allowing for the distribution of its products to a broader customer base.

2Emerging Markets

Ashish Life Science Private Limited has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's commitment to quality and regulatory compliance has enabled it to establish partnerships and distribution networks in these regions. By obtaining approvals from international health authorities, including the World Health Organization (WHO), the company has facilitated the registration and marketing of its products in various countries. This strategic approach has enhanced the company's global footprint, allowing it to serve a diverse clientele and contribute to the improvement of animal health worldwide.

Ashish Life Science Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of March 2026, specific details regarding Ashish Life Science Private Limited's interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not publicly available. The company's focus on international markets, particularly in Europe and Australia, suggests that its primary regulatory engagements may be with agencies such as the European Medicines Agency (EMA) and the Australian Therapeutic Goods Administration (TGA). For comprehensive information on FDA-related activities, direct inquiries to the company or the FDA would be advisable.

2WHO & EU GMP

Ashish Life Science Private Limited's manufacturing facility in Tarapur, Maharashtra, has been approved by the World Health Organization Good Manufacturing Practice (WHO GMP) and the European Union Good Manufacturing Practice (EU GMP). These certifications affirm the company's commitment to maintaining high-quality manufacturing standards and adhering to international regulatory requirements. The EU GMP certification, in particular, facilitates the company's access to European markets, enabling the export of its veterinary pharmaceutical products to a broader customer base.

Ashish Life Science Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the veterinary pharmaceutical sector, Ashish Life Science Private Limited faces competition from both domestic and international companies. While specific market share data is not publicly available, the company's extensive product portfolio and international certifications position it favorably in the market. The company's focus on quality, regulatory compliance, and customer satisfaction differentiates it from competitors, enabling it to establish strong relationships with partners, distributors, and key retailers across more than 60 countries.

2Key Differentiators

Ashish Life Science Private Limited's key differentiators include its adherence to international quality standards, as evidenced by certifications such as WHO GMP and EU GMP. The company's diverse product portfolio, encompassing various veterinary dosage forms, and its ability to customize formulations to meet client specifications further distinguish it in the market. Additionally, the company's global presence and commitment to regulatory compliance enhance its competitive advantage.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Ashish Life Science Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Ashish Life Science Private Limited has demonstrated a strong track record in pharmaceutical manufacturing, with a total export value of $483,000 USD and 94 shipments across five products in two therapeutic categories. The company's portfolio concentration is notable, with its top five products accounting for 100% of its exports. This focus on a select range of products indicates a strategic approach to market penetration and product specialization. The company's adherence to international quality standards and regulatory requirements further underscores its reliability as a supplier.

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Ashish Life Science Private Limited

How many pharmaceutical products does Ashish Life Science Private Limited export from India?

Ashish Life Science Private Limited exports 5 pharmaceutical products across 2 therapeutic categories. The top exports are Ivermectin ($138.4K), Praziquantel ($101.9K), Levamisole ($93.6K), Streptomycin ($92.5K), Pyrantel ($56.4K). Total export value is $482.8K.

What is Ashish Life Science Private Limited's total pharmaceutical export value?

Ashish Life Science Private Limited's total pharmaceutical export value is $482.8K, based on 94 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Ashish Life Science Private Limited cover?

Ashish Life Science Private Limited exports across 2 therapeutic categories. The largest are Antimalarial & Antiparasitic (80.8%, 4 products), Antibiotics (19.2%, 1 products).

Get Full Ashish Life Science Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.